Syndax Pharmaceuticals (SNDX) Gross Profit (2024 - 2026)

Syndax Pharmaceuticals' Gross Profit history runs 3 years deep, the most recent figure standing at $53.0 million for Q1 2026.

• In Q1 2026, Gross Profit rose 176.76% year-over-year to $53.0 million; the TTM figure through Mar 2026 stood at $186.4 million (up 391.78% YoY), while the FY2025 annual figure was $138.6 million, up 639.06% from the prior year.
• Gross Profit was $53.0 million for Q1 2026 at Syndax Pharmaceuticals, down from $59.1 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $59.1 million in Q4 2025 to a low of $2.8 million in Q4 2024.
• Historically, Gross Profit has averaged $28.0 million across 3 years, with a median of $27.9 million in 2025.
• The sharpest annual moves came in 2025 and 2026: Gross Profit jumped 2050.36% in 2025, then jumped 176.76% in 2026.
• A 3-year view of Gross Profit shows it stood at $2.8 million in 2024, then surged by 2050.36% to $59.1 million in 2025, then decreased by 10.34% to $53.0 million in 2026.
• The last three Gross Profit figures came in at $53.0 million (Q1 2026), $59.1 million (Q4 2025), and $37.6 million (Q3 2025), per Business Quant data.